Sab Biotherapeutics, Inc. · NASDAQ:SABS
Sab Biotherapeutics — Biotech Showcase Conference January 2023
22 slides from Sab Biotherapeutics's conference presentation, Jan 9, 2023
Slide 1: Next Generation Biologics in Immunology Solution for Complex Diseases
Next Generation Biologics in Immunology Solution for Complex Diseases Biotech Showcase Conference January 2023 Alexandra Kropotova, MD Executive Vice President & Chief Medical Officer Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (“SAB”) and is general background information about SAB’s activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete
Slide 3: SAB Biotherapeutics Fact Sheet
SAB Biotherapeutics Fact Sheet 2 11 90 700 0 1 Years or less from concept to IND filing Anti-infective assets with proven efficacy in Discovery or Development stages Percent success rate from concept to IND and beyond Subjects treated with SAB therapeutics in clinical trials across DIVERSITAB platfo
Slide 4: Demonstrated as a Novel Discovery Platform for Human Monoclonal and Polyclonal Antibodies
Demonstrated as a Novel Discovery Platform for Human Monoclonal and Polyclonal Antibodies Antigen Titer/Potency Monitoring Hyper Immunization with Antigen Patented animals produce human antibodies Targeted Human Antibody Production Downstream Processes: Antigen specific Fluorescence Activated Cell S
Slide 5: Significant Gains in R&D Efficiency with SAB hpAb Discovery & CMC Production
5 Significant Gains in R&D Efficiency with SAB hpAb Discovery & CMC Production Antigen Design & Development SAB hpAb therapeutics: Simultaneous “discovery” and CMC production in Tc Bovine Traditional mAbs therapeutics: Sequential discovery and CMC production process Discovery & Production Purificati
Slide 6: Fully-Human, Diverse Repertoire, & Functional Antibodies
Fully-Human, Diverse Repertoire, & Functional Antibodies VDJ repertoire usage mimics human-derived diversity in variable region Rich Antibody Diversity Highly-Functional Fc Region Matches full activation of effector cells and functional glycosylation / post translational modification © 2023 SAB BIOT
Slide 7: Key Product Differentiators vs Monoclonal Antibodies
Key Product Differentiators vs Monoclonal Antibodies: Multi-target capability in a single therapeutic Natural multi-epitope targeted pAb selected and produced in vivo Ability to target multiple disease pathways at once increase potential for superior efficacy Specifically driven high-potency antibod
Slide 8: Biologic Pipeline with Broad Polyclonal Therapeutic Reach
Biologic Pipeline with Broad Polyclonal Therapeutic Reach © 2023 SAB BIOTHERAPEUTICS, INC.
Slide 9: Clinical Development Programs: Asset Progress
Clinical Development Programs: Asset Progress SAB-195 IND (CDI, targeting H2 2023-H1 2024) SAB-176 2023-2024 flu season Phase 2b FPI SAB-142 IND (T1D) SAB-142 Phase 1/POBA FPI SAB-195 Phase 1/POBA FPI SAB-195 Phase1/POBA topline SAB-176 2023-2024 flu season Phase 2b topline SAB-142 Phase 1/P
Slide 10: Value Proposition: SAB-176
Value Proposition: SAB-176 First and only broadly neutralizing polyclonal biologic for prophylaxis and treatment of influenza in high-risk patients Adaptive and cross-reactive to multiple influenza strains Multiprong Mechanism of Action Neutralizing activity targeting multiple epitopes of Influenza
Slide 11: SAB-176 Protected Mice from Weight Loss While Oseltamivir Didn't
0% survival in 100mg/kg/d Oseltamivir-treated groups SAB-176 Protected Mice from Weight Loss While Oseltamivir Didn’t Efficacy Against Mutational Drift: Oseltamivir Resistant (OR) H1N1pdm Virus Challenge Model 11 SAB-176 Showed 100% Protection at All Dose Levels From Mortality © 2023 SAB BIOTHERAPEU
Slide 12: Established Proof-of-Concept for SAB-176: Met Primary Endpoint in Phase 2a
Established Proof-of-Concept for SAB-176: Met Primary Endpoint of Viral Load Reduction in Phase 2a Challenge Study Mean Viral Load by Nasal Samples qRT-qPCR by Day Relative to Viral Challenge 12 Mean Total Symptom Score by Day Relative to Viral Challenge SAB-176 Achieved Statistically Significant (p
Slide 13: Only SAB-176 Provides Potential for Evergreen Biologic
Comprehensive approach to treating high-risk patients with influenza by broadly neutralizing fully-human pAb immunotherapeutic with several anti-viral mechanisms © 2022 SAB BIOTHERAPEUTICS, INC. Only SAB-176 Provides Potential for “EVERGREEN” Biologic with Low Risk of Escape Mutants © 2023 SAB BIOTH
Slide 14: Value Proposition: SAB-195
Value Proposition: SAB-195 First-in-class fully human polyclonal antibody treatment targeting C Diff spores, bacteria, and toxins Only treatment with dual mode of action: Unlike bezlotoxumab, SAB-195 targets surface antigens on C. diff bacteria and spores Unlike antibiotics, SAB-195 targets several
Slide 15: SAB-195 Preclinical Data
SAB-195 Preclinical Data Tc bovine Immunized with Antigen Fusion Proteins Constructed from Receptor Binding Domain of C. diff Toxin A (TcdA), C. diff Toxin B (TcdB)(630) and (TcdB)(027) and Binary Toxin (CDT) Tc bovine-derived anti-quadrivalent toxin hIgG provided 90% to 100% protection in hamsters
Slide 16: Only SAB-195 Can Target Multiple C. diff Antigens and Toxins in One Therapeutic
Only SAB-195 Can Target Multiple C. diff Antigens and Toxins in One Therapeutic Comprehensive approach to treating patients with CDI addresses the entire life cycle of the C. diff pathogen and disease pathophysiology © 2023 SAB BIOTHERAPEUTICS, INC.
Slide 17: Value Proposition: SAB-142
Value Proposition: SAB-142 First-in-class fully human polyclonal antibody treatment aimed to provide superior efficacy for delaying onset and progression of clinical Stage 3 T1D Validated Mechanism of Action by a 3rd party ATG demonstrating reduction in loss of C-peptide vs. placebo (Haller, 2019) F
Slide 18: SAB-142 Demonstrates Similar Activity to Approved Rabbit ATG
SAB-142 Demonstrates Similar Activity to Approved Rabbit Anti-Thymocyte Globulin (ATG) CD8 T Cells Treg Cells Live cells in CD8* gate Live CD4+CD25+Foxp3- Activated CD4 T Cells Live CD4+CD25+Foxp3- Naïve CD4 T Cells Live CD4+CD25+Foxp3- SAB-142 Targets CD4+, CD8+ and Protects T-Regulatory Cells © 20
Slide 19: SAB-142: GLP Tox Study Results Enable IND Submission
SAB-142: GLP Tox Study Results Enable IND Submission © 2023 SAB BIOTHERAPEUTICS, INC. Objectives: Determine the potential toxicity of SAB-142 vs. an anti-thymocyte globulin (ATG) when given by single intravenous infusion to non-human primates Characterize mechanism of action, toxicokinetic & immunog
Slide 20: SAB-142: MoA Clinically Validated by 3rd Party Compound
SAB-142: MoA Clinically Validated by 3rd Party Compound 2 Years: Low-Dose ATG* Preserved C-Peptide in New Onset T1D 20 p=0.00005 ATG vs Placebo Placebo *RABBIT ATG FROM SANOFI – NOT SAB-142 (HUMAN TC-BOVINE DERIVED ATG) Haller et al. Diabetes. 2019. June, 68(6): 1267-1276 EQUINE ATGAM-AF488 Tc Bovin
Slide 21: Comprehensive approach to treating Stage 2/3 T1D with SAB-142
Comprehensive approach to treating Stage 2/3 T1D with fully-human pAb anti-thymocyte immunotherapeutic © 2022 SAB BIOTHERAPEUTICS, INC. SAB-142: Only Fully-Human Polyclonal Anti-Thymocyte Immunoglobulin © 2023 SAB BIOTHERAPEUTICS, INC.
Slide 22: Summary
Summary 22 DIVERSITABTM Platform: Innovative DiversitAb™ platform produces a new class of targeted fully-human, highly-potent polyclonal antibodies, with a broad efficacy spectrum in a broad range of indications. Platform is well-positioned to address complex diseases with targeting multiple epitope
SAB Biotherapeutics — Biotech Showcase Conference January 2023 on 6ix